Z-1074-2022 Class II Ongoing
FDA device recall Z-1074-2022 was initiated by Daavlin Distributing Company on Apr 26, 2022 and is designated Class II. Reason for recall: Software issue, resuming an interrupted treatment will result in swap of utilized calibration treatment distance 0" inches to "9. Resulting in over or under dosing. The recall status is ongoing. Affected quantity: 1.
Recall details
- Product Type
- Devices
- Report Date
- May 18, 2022
- Initiation Date
- Apr 26, 2022
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 1
Product description
4 Series CX phototherapy units equipped with Daavlin's ClearLink Control System software versions v3.03h and 3.04v. M4 Ser CX 311-20 120-240V 50/60Hz, item # 807QS0020CX6.
Reason for recall
Software issue, resuming an interrupted treatment will result in swap of utilized calibration treatment distance 0" inches to "9. Resulting in over or under dosing.
Distribution pattern
Worldwide distribution - US Nationwide distribution in the states of AL, AR, AZ, CA, CO, CT, DE, FL, GA, IA, ID, IL, IN, KS, KY, LA, MA, MD, MI, MN, MO, MS, MT, NC, NE, NH, NJ, NY, OH, OK, OR, PA, SD, TN, TX, VA, WA, WI, WV and the countries of Australia, Canada.
Code information
UDI-DI: +B2809807QS0020CX60L. Serial Number: QS11571PLNBCX0020
Source
- Dataset
- openFDA device recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for Z-1074-2022
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026